Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioSante Pharmaceuticals
CaP nanotechnology review presented at immunopotentiators meeting
June 15th, 2005
BioSante Pharmaceuticals (BPA) announced that Steve Bell, vice president of research and preclinical development for BioSante, presented a review of progress with BioVant, the company's patented calcium phosphate (CaP) nanoparticle technology, at the Second International Conference on Immunopotentiators in Modern Vaccines (IMV 2005) meeting in Malaga, Spain. The presentation was entitled, "Calcium Phosphate Nanoparticles versus Microparticles: Selective Th1 versus Th2 Immunity." Bell also provided a review of progress toward the use of BioVant for "rational vaccine design." Based upon careful analysis of immune response results in preclinical testing...
Source: Physician Law Weekly (2005-06-15)
|
